Biotechnology

Solaxa Announces Phase 3 Clinical Trial for Spinocerebellar Ataxia Type 27B

March 28, 2025 12:00 PM

Solaxa Inc., a biopharmaceutical public benefit corporation focused on rare neurological conditions, has announced plans to conduct a registrational clinical trial evaluating its investigational therapy, SLX-100, for spinocerebellar ataxia type 27B (SCA27B). This pivotal-powered study will be funded in part by a $7.3 million dollar grant awarded to Dr. Susan Perlman, MD, at the University of California, Los Angeles by the Congressionally...

Read more

Prolocor(R) Announces Publication in Circulation: Cardiovascular Interventions. Results Demonstrate That the Prolocor pFCG(TM) Test Predicts Risk of Subsequent Cardiovascular Events Regardless of Treatment Strategy (Percutaneous Coronary Intervention or Medical Management Alone)

March 28, 2025 9:00 AM

Prolocor, Inc., a healthcare startup developing the innovative diagnostic Prolocor pFCGTM test that identifies patients at higher and lower risk of thrombotic events (heart attack, stroke, and death), announced today a publication entitled Predictive Value of Platelet FcγRIIa in Patients Treated with Percutaneous Coronary Intervention Compared with Medical Therapy Alone after Myocardial Infarction in the journal Circulation: Cardiovascular...

Read more

Vicore to Participate in the Van Lanschot Kempen Life Sciences Conference

March 28, 2025 3:10 AM

Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that Ahmed Mousa, Chief Executive Officer, will be a panelist during the idiopathic pulmonary fibrosis (IPF) plenary session at the 2025 Van Lanschot Kempen Life Sciences Conference. Location: Amsterdam, the Netherlands Panelist: Ahmed Mousa, CEO IPF Plenary Session Date and Time: Wednesday,...

Read more

Aspira Women's Health Reports Fourth Quarter and Full Year 2024 Financial Results

March 27, 2025 4:00 PM

Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year ended December 31, 2024. Select financial results are as follows: Fourth Quarter 2024 and Recent Financial Highlights • Product revenue increased 9.5% to $2.3 million for the three months ended...

Read more

Alligator Bioscience Publishes Annual Report for 2024

March 27, 2025 2:30 PM

Alligator Bioscience (STO:ATORX) today announced that the Annual Report for 2024, as well as the company's Remuneration Report, has been published. Because of environmental and cost reasons, Alligator Bioscience has chosen not to print the annual report. The Annual Report and the Remuneration Report are attached as PDFs and are available on the company's website. For further information, please contact: Søren Bregenholt, CEO E-mail:...

Read more

Minutes from Annual General Meeting in FluoGuide A/S

March 27, 2025 11:15 AM

FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company" held its annual general meeting on 27 March 2025. To the shareholders of FluoGuide A/S. The Annual General Meeting was held Thursday 27 March 2025 at 02:00 PM (CET) at the Company's premises Titanhus, Titangade 9-13, meeting room - Kronos, DK-2200 Copenhagen N, Denmark. Notice: Represented at the annual general meeting was share capital of nominal DKK 596,840.70 corresponding to 5,968,407...

Read more

Bulletin from the Extraordinary General Meeting in Alligator Bioscience AB

March 27, 2025 9:30 AM

Alligator Bioscience (STO:ATORX) Today, on 27 March 2025, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follows below. Resolution on guidelines for remuneration to senior executives The meeting resolved, in accordance with the board of directors' proposal, to adopt new guidelines for remuneration to the company's senior executives. Resolution on reduction of the share capital to cover...

Read more

Imagene Laboratory Receives Accreditation From College of American Pathologists

March 27, 2025 9:15 AM

The Accreditation Committee of the College of American Pathologists (CAP) has recently awarded accreditation to Imagene Laboratory, Phoenix, Arizona, based on the results of a recent on‐site inspection as part of CAP's Accreditation Programs. Recognized for rigorous and robust standards, CAP accreditation elevates quality and mitigates risk, an important way that laboratories can contribute to improved patient outcomes. "We are proud that the...

Read more

Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at 2025 Annual MDS Foundation Congress

March 27, 2025 3:20 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) New analysis and biomarker data strengthens understanding of bexmarilimab's potential TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, today announces that data from its ongoing BEXMAB study evaluating bexmarilimab in patients with high-risk myelodysplastic syndromes (HR-MDS) have been...

Read more

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma

March 26, 2025 9:00 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. ("PeriNess"), has entered into a Clinical Study Agreement (the "Agreement") to support an exploratory clinical study of Xenetic's systemic DNase I candidate, XBIO-015, in patients with...

Read more

IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

March 26, 2025 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced additional positive interim results from its ongoing Phase 2 clinical trial on IGC-AD1, an investigational treatment for agitation in dementia due to Alzheimer's disease. Based on the interim analysis at week 2 sleep disturbance was reduced by about 71% (p=.012) and at week 6 about 78% (p=.02) for those on the active medication. These values indicate a...

Read more

Notice of Annual General Meeting of Vicore Pharma Holding AB (publ)

March 26, 2025 4:00 AM

Vicore Pharma Holding (STO:VICO) The shareholders of Vicore Pharma Holding AB (publ), Reg. No. 556680-3804 ("Vicore Pharma" or the "company"), with its registered offices in Stockholm, are summoned to the Annual General Meeting on Tuesday 6 May 2025 at 15.00 in the premises of the law firm Vinge at Smålandsgatan 20, SE-111 46 Stockholm, Sweden. Registration starts at 14.45. Shareholders can participate in the Annual General Meeting by attending...

Read more

Vicore Publishes the Annual Report for 2024

March 26, 2025 3:20 AM

Vicore Pharma Holding (STO:VICO) Stockholm, March 26, 2025 - Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced the publication of the Annual Report for the financial year 2024. The Annual Report for the financial year 2024 is available on the company's website: https://vicorepharma.com/investors/financial-reports/ For further information,...

Read more

DiviTum(R) TKa Data in Combination with Inflammation Proteins Presented at the AACR Meeting Enhance Precision to Predict Efficacy of Immunotherapy

March 26, 2025 3:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, a leader in blood-based biomarker assays in oncology, today announces that an abstract with DiviTum TKa in a biomarker algorithm will be presented by Karolinska Institutet (KI) at the annual AACR meeting in Chicago on April 25-30, 2025, providing the first evidence that DiviTum TKa in combination with inflammation protein biomarkers significantly improves the ability to...

Read more

Notice to Annual General Meeting in BioInvent International AB

March 25, 2025 5:20 AM

BioInvent International (STO:BINV) The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting to be held at 4.00 p.m., 29 April 2025 at Elite Hotel Ideon on Scheelevägen 27 in Lund, Sweden. The Board of Directors has decided that shareholders shall be able to exercise their voting rights at the Annual General Meeting also by voting in advance by post in accordance with the...

Read more

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

March 24, 2025 8:00 AM

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its novel oral antibody, TH023. In a murine model, a proprietary protease enzyme stabilized platform demonstrated successful delivery of infliximab, a tumor necrosis factor-alpha (TNF-α) inhibitor, in serum with concentrations detected being significantly...

Read more

Nature Cell’s JointStem Becomes the First Korean Company to Acquire Breakthrough Therapy Designation from the U.S. FDA

March 22, 2025 12:00 PM

Nature Cell Co., Ltd., a leading biotechnology company announced on March 20th that JointStem, currently undergoing clinical trials in the United States, has been granted Breakthrough Therapy Designation (BTD) from the U.S. FDA- the first instance for a Korean company in the field of cell therapy. The Breakthrough Therapy Designation is granted by the FDA to clinical trials that demonstrate a clinically significant improvement over existing...

Read more

Alligator Bioscience Announces Leadership Transition in Clinical Development

March 21, 2025 1:00 PM

Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces that Dr. Sumeet Ambarkhane MD, Chief Medical Officer, will be leaving Alligator by end of March 2025. Dr. Ambarkhane has played a key role in advancing Alligator's immune-oncology pipeline and establishing its clinical development organization over the past years. In particular, he led the clinical development of mitazalimab and OPTIMIZE-1, Alligator's Phase 2 trial in metastatic...

Read more

Elizabeth Fraley, CEO of Kinder Ready Offers a Comprehensive Guide to Navigating the Private School Application Process

March 21, 2025 12:00 PM

Navigating the private school application process can be a complex and overwhelming experience for parents. From researching schools and completing applications to preparing for interviews, the journey requires careful planning and insight. To support families in making informed decisions, Elizabeth Fraley Kinder Ready provides a step-by-step guide to simplify the process. Elizabeth Fraley Kinder Ready has established itself as a leader that...

Read more

Board Changes

March 21, 2025 9:30 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)(AIM: FARN) (First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, is pleased to announce the appointment of Dr Juho Jalkanen to the Board of Directors as an Executive Director and Mr. Colin Bond to the Board of Directors as a Non-executive Director of...

Read more